

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2018/015433 A2

(43) International Publication Date
25 January 2018 (25.01.2018)

(51) International Patent Classification:

G06F 19/00 (2011.01) C12Q 1/68 (2006.01)

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2017/068226

(22) International Filing Date:

19 July 2017 (19.07.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2016/067348

20 July 2016 (20.07.2016) EP

(71) Applicant: BIONTECH RNA PHARMACEUTICALS GMBH [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE).

(72) Inventors: TADMOR, Arbel D.; Am Anger 10, 55294 Bodenheim (DE). SAHIN, Ugur; Philipp-von-Zabern-Platz 1, 55116 Mainz (DE).

(74) Agent: SCHNAPPAUF, Georg; ZSP Patentanwälte PartG mbB, Hansastrasse 32, 80686 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: SELECTING NEOEPITOPES AS DISEASE-SPECIFIC TARGETS FOR THERAPY WITH ENHANCED EFFICACY

(57) Abstract: The present invention relates to methods for determining whether neopeptides that are only expressed in or on diseased cells are suitable disease-specific targets, such that the diseased cell is less likely to be able to escape immune surveillance, and use of the neopeptides in providing an immune response against diseased cells expressing the neopeptides.

WO 2018/015433 A2